Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

SkinMedica Buys Facial Hair Treatment Vaniqa From Women First HealthCare

This article was originally published in The Pink Sheet Daily

  • News
  • Catherine Harrison

Executive Summary

The $36.6 mil. deal represents the second time Vaniqa is changing hands in as many years. SkinMedica will re-launch the product with a focus on dermatologist detailing.

You may also be interested in...



Women First Healthcare Seeks Buyer

Women First Healthcare is looking for a buyer to avoid filing for Chapter 11 bankruptcy

Bristol To Name New R&D Head Shortly

Senior VP-Global Clinical & Pharmaceutical Development Elliott Sigal is acting president of Bristol-Myers Squibb’s research institute following the death of James Palmer.

Aranesp Performance Strong Heading Into "Transition" Time, Amgen Says

The company is talking with oncologists about Aranesp ahead of a switch in Medicare reimbursement in January 2005. U.S. sales for the red blood cell product were up 32% in the third quarter.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS059823

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By